Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma
Authors:
Open Access
- 7 January 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 47 (5) , 1524-1532
Abstract
Primary liver cancer, hepatocellular carcinoma (HCC), is the fifth most common cancer and the third leading cancer killer in the world. There is no effective therapeutic option for most HCC patients. A new therapeutic strategy is essential. Granulin-epithelin precursor (GEP, also called progranulin, acrogranin, or PC-derived growth factor) was identified as a potential therapeutic target for HCC from our earlier genome-wide expression profiles. We aimed to conduct a detailed investigation with in vitro and animal experiments. We developed the anti-GEP monoclonal antibody (mAb), and examined its effect on hepatoma cells and normal liver cells in vitro . A nude mice model transplanted with human HCC was used to investigate if anti-GEP mAb can inhibit tumor growth in vivo . We demonstrated that anti-GEP mAb inhibited the growth of hepatoma cells but revealed no significant effect on normal liver cells. In the nude mice model transplanted with human HCC, anti-GEP mAb decreased the serum GEP level and inhibited the growth of established tumors in a dose-dependent manner. The anti-GEP mAb reduced tumor cell proliferation via the p44/42 MAPK and Akt pathways, and reduced tumor angiogenesis to deprive the nutrient supply with reduced microvessel density and tumor vascular endothelial growth factor level. Conclusion: We have shown that anti-GEP antibody can inhibit HCC growth, providing evidence that GEP is a therapeutic target for HCC treatment.Keywords
Funding Information
- Sun C.Y. Research Foundation for Hepatobiliary and Pancreatic Surgery
- Seed Funding Program of the University of Hong Kong
- Hong Kong Research Grants Council (HKU 7392/03M, HKU 7560/06M)
This publication has 29 references indexed in Scilit:
- Mechanisms of Disease: the complement system in renal injury—new ways of looking at an old foeNature Clinical Practice Nephrology, 2007
- Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17Nature, 2006
- New therapies for hepatocellular carcinomaOncogene, 2006
- Increased expression of glycosyl‐phosphatidylinositol anchor attachment protein 1 (GPAA1) is associated with gene amplification in hepatocellular carcinomaInternational Journal of Cancer, 2006
- Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinomaInternational Journal of Clinical Oncology, 2006
- The role of complement in autoimmune renal diseaseAutoimmunity, 2006
- Systemic therapies for hepatocellular carcinomaExpert Opinion on Investigational Drugs, 2004
- Gene expression microarray technologies in the development of new therapeutic agentsEuropean Journal of Cancer, 2004
- Decreased expression of cytochrome P450 2E1 is associated with poor prognosis of hepatocellular carcinomaInternational Journal of Cancer, 2004
- PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cellsCarcinogenesis, 2004